NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer NDTV Profit's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Direct Report
Emcure Pharmaceutials Ltd.'s domestic business combines a strong position in chronic and acute therapies, leadership in Women 's care , a sizeable Injectables franchise and a differentiated front - end platform through Zuventus, says the brokerage.
Importantly, the company has multiple relatively low - risk growth opportunities through strategic in -licensing partnerships with global innovators, providing access to established products and emerging therapy areas without incurring significant R&D investments.
The GLP -1 opportunity, expansion into MASH, Ophthalmics, Dermatology and Consumer Health provide additional optionality beyond the core portfolio. Internationally, Emcure has built strong front -end capabilities through a well -executed acquisition -led strategy in Canada and Europe, while maintaining a vertically integrated supply chain through its Indian manufacturing base.
Its large and diversified product pipeline, presence in complex generics and differentiated opportunities such as Semaglutide, Liposomal Amphotericin B and Lenacapavir strengthen medium -term growth visibility.
The combination of a diversified domestic franchise, scalable international platforms, proven M&A execution and multiple complex -product opportunities offer a stronger and more diversified growth profile.
The brokerage values Emcure Pharma at Rs 2305 per share, based on 30 times FY28E EPS of Rs 76 .8.
ALSO READ: Can V2 Retail Shares Double? Motilal Oswal Initiates Coverage With 'Buy' — Check Bull, Bear Cases
Key Risk and Concerns
- Unsuccessful/Delayed integration of acquired/in -licensed portfolios
- Delay in product approvals in Canada.
- Inability to attract/retain R&D talent
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
